PROpel研究:奥拉帕利联合阿比特龙治疗mCRPC的患者报告结局
PROpel 3期研究显示,奥拉帕利+阿比特龙一线治疗转移性去势抵抗性前列腺癌(mCRPC)较安慰剂+阿比特龙显著改善影像学无进展生存期(rPFS)。本次报告患者报告结局:两组FACT-P总分及各子量表、BPI-SF最痛评分、疼痛严重程度及疼痛干扰评分较基线的变化均无总体差异。提示联合方案在维持与标准治疗相似的健康相关生活质量(HRQoL)的同时可带来临床获益。
要点
- 奥拉帕利+阿比特龙组与安慰剂+阿比特龙组的FACT-P总分及子量表变化无总体差异。
- 两组BPI-SF最痛评分、疼痛严重程度及疼痛干扰评分较基线变化均无总体差异。
- 联合方案在维持与标准治疗相似HRQoL的同时可带来临床获益。
核心结论
- mCRPC患者接受奥拉帕利+阿比特龙与安慰剂+阿比特龙相比,患者报告的健康相关生活质量和疼痛评分无差异。
研究设计与样本
- 3期PROpel研究,患者按1:1随机分配至奥拉帕利(300 mg每日两次)或安慰剂,均联合阿比特龙醋酸酯(1000 mg每日一次)加泼尼松或泼尼松龙。
- 筛查1103例患者,399例随机至奥拉帕利+阿比特龙组,397例至安慰剂+阿比特龙组。
- 患者报告结局为预设次要终点,评估工具包括FACT-P(健康相关生活质量)和BPI-SF(疼痛),数据截止2022年10月12日。
主要发现
- FACT-P总分及各子量表较基线的最小二乘均值变化在两组间无总体差异。
- BPI-SF最痛评分、疼痛严重程度及疼痛干扰评分较基线的变化在两组间无总体差异。
临床怎么用
- 对于mCRPC患者,奥拉帕利+阿比特龙在改善rPFS的同时,健康相关生活质量和疼痛控制与当前标准治疗(安慰剂+阿比特龙)相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The phase 3 PROpel study showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) with olaparib + abiraterone versus placebo + abiraterone in the first-line setting for patients with metastatic castration-resistant prostate cancer (mCRPC) unselected by mutation status for homologous recombination repair genes. Here we report patient-reported outcomes and results for other symptom-related endpoints. METHODS: Patients were randomized 1:1 to either olaparib (300 mg twice daily) or placebo, both given with abiraterone acetate (1000 mg once daily) plus prednisone or prednisolone. The primary endpoint was rPFS (at planned primary analysis; data cutoff July 30, 2021). Prespecified secondary endpoints included patient-reported outcomes evaluating health-related quality of life (HRQoL; Functional Assessment of Cancer Therapy-Prostate [FACT-P]) and pain (Brief Pain Inventory-Short Form [BPI-SF]) (prespecified final analysis of overall survival; data cutoff October 12, 2022). KEY FINDINGS AND LIMITATIONS: Between October 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomized to olaparib + abiraterone and 397 to placebo + abiraterone. There were no overall differences between the treatment arms in the least-squares mean change from baseline in FACT-P total score or subscales, or in BPI-SF scores for worst pain, pain severity, and pain interference. CONCLUSIONS AND CLINICAL IMPLICATIONS: In PROpel, there were no differences in HRQoL or pain scores reported by patients with mCRPC receiving olaparib + abiraterone versus placebo + abiraterone, suggesting that patients can derive a clinical benefit from olaparib + abiraterone while maintaining similar HRQoL in comparison with current standard-of-care treatment. The PROpel trial is registered on ClinicalTrials.gov as NCT03732820.
引用
- Armstrong AJ, Saad F, Oya M, et al. Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study. Eur Urol Oncol. 2025. PMID: 41253648. doi:10.1016/j.euo.2025.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。